SCHEMBL5381872

SCHEMBL5381872

CSc1nsc(OCc2ccc(Cl)cc2)n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.56
CYP1A2 P05177 2/20 0.56
CYP2C9 P11712 2/20 0.56
CYP2C19 P33261 2/20 0.56
MEN1 O00255 1/20 0.55
KMT2A Q03164 1/20 0.55
PTGS1 P23219 1/20 0.46
PTGS2 P35354 1/20 0.46
HSP90AA1 P07900 1/20 0.40
TDP1 Q9NUW8 3/20 0.40
MAPT P10636 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPK1 P28482 1/20 0.40
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
MAOB P27338 4/20 0.37
APP P05067 1/20 0.37
DHFR P00374 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5417437 0.87 MEN1 (0.41) L3MBTL1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL5378069 0.87 CYP1A2 (0.47) L3MBTL1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL5383575 0.85 APP (0.42) L3MBTL1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL5378771 0.85 TDP1 (0.56) L3MBTL1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL5373434 0.85 CYP1A2 (0.43) L3MBTL1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL5378052 0.85 MEN1 (0.41) L3MBTL1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL5377736 0.85 LMNA (0.47) L3MBTL1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL5378121 0.85 MEN1 (0.44) L3MBTL1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL5389477 0.85 L3MBTL1 (0.43) L3MBTL1CYP1A2CYP2C9CYP2C19MEN1
SCHEMBL5375690 0.84 RAB9A (0.45) L3MBTL1CYP1A2CYP2C9CYP2C19MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-20070293510-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) 2007-12-20 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-7273879-B2 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-09-25 US disclosed
US-20050215578-A1 Thiadiazole compounds and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2005-09-29 US disclosed
EP-1475374-A1 THIADIAZOLE COMPOUNDS AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2004-11-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215578-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH L3MBTL1 26/4885CYP1A2 24/4885CYP2C9 107/4885
US-20070293510-A1 Thiadiazole compounds and use thereof C5, C3AR1, TH L3MBTL1 25/4885CYP1A2 30/4885CYP2C9 113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.